tiprankstipranks
Advertisement
Advertisement
Beam Therapeutics price target lowered to $39 from $40 at Bernstein
PremiumThe FlyBeam Therapeutics price target lowered to $39 from $40 at Bernstein
1M ago
FDA Commissioner Marty Makary resigns
Premium
The Fly
FDA Commissioner Marty Makary resigns
1M ago
Analyst Maintains Buy on Beam Therapeutics, Reiterates $75 Price Target Amid Pipeline Progress and De-Risking Milestones
Premium
Ratings
Analyst Maintains Buy on Beam Therapeutics, Reiterates $75 Price Target Amid Pipeline Progress and De-Risking Milestones
1M ago
Beam Therapeutics: Compelling BEAM-302 Data and Manageable Safety Profile Underpin Buy Rating and Favorable Risk‑Reward
PremiumRatingsBeam Therapeutics: Compelling BEAM-302 Data and Manageable Safety Profile Underpin Buy Rating and Favorable Risk‑Reward
2M ago
Beam Therapeutics’ risto-cel shows efficacy in Sickle Cell Disease trial
Premium
The Fly
Beam Therapeutics’ risto-cel shows efficacy in Sickle Cell Disease trial
2M ago
Beam Therapeutics price target raised to $68 from $64 at Citi
Premium
The Fly
Beam Therapeutics price target raised to $68 from $64 at Citi
3M ago
Beam Therapeutics Earnings Call Highlights PKU Pivot
PremiumCompany AnnouncementsBeam Therapeutics Earnings Call Highlights PKU Pivot
3M ago
Beam Therapeutics: Advancing Interventional Genetics With Strong Balance Sheet and Multiple Near-Term Catalysts Supporting Buy Rating
Premium
Ratings
Beam Therapeutics: Advancing Interventional Genetics With Strong Balance Sheet and Multiple Near-Term Catalysts Supporting Buy Rating
3M ago
Beam Therapeutics price target raised to $26 from $22 at RBC Capital
Premium
The Fly
Beam Therapeutics price target raised to $26 from $22 at RBC Capital
4M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100